Orbimed Advisors LLC reported 110 positions worth $5.09B for the quarter ended Jun 30, 2026, up 19.8% on the prior quarter. It opened 30 new positions, added to 29, trimmed 25 and exited 16. Its largest holding is Edgewise Therapeutics, Inc. at 12.4% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| UNH Unitedhealth Group Inc | +161.1K | – | $66.96M | 1.32% |
| HUM Humana Inc | +164.1K | – | $65.18M | 1.28% |
| ODTX Odyssey Therapeutics, Inc. | +3.00M | – | $56.15M | 1.1% |
| ARQT Arcutis Biotherapeutics, Inc. | +2.04M | – | $53.54M | 1.05% |
| COGT Cogent Biosciences, Inc. | +1.36M | +422.0% | $52.60M | 1.28% |
| AZN Astrazeneca Plc | +245.5K | +36.6% | $45.87M | 3.36% |
| GPCR Structure Therapeutics Inc. | +734.0K | +49.7% | $39.39M | 2.33% |
| WST West Pharmaceutical Services Inc | +70.6K | – | $25.35M | 0.498% |
| LLY ELI LILLY & Co | +21.1K | +8.9% | $25.31M | 6.08% |
| PVLA Palvella Therapeutics, Inc. | +157.8K | +117.2% | $24.11M | 0.878% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| ELVN Enliven Therapeutics, Inc. | -1.18M | -14.9% | $60.03M | 6.76% |
| PFE Pfizer Inc | -1.95M | -100.0% | $54.66M | Exited |
| IRON Disc Medicine, Inc. | -710.0K | -66.5% | $51.93M | 0.514% |
| DHR Danaher Corp | -265.8K | -100.0% | $50.40M | Exited |
| SION Sionna Therapeutics, Inc. | -974.8K | -27.6% | $42.88M | 2.21% |
| ARGX Argenx Se | -44.0K | -32.2% | $40.84M | 1.69% |
| BSX Boston Scientific Corp | -898.9K | -37.7% | $38.37M | 1.24% |
| EW Edwards Lifesciences Corp | -395.7K | -32.2% | $35.80M | 1.49% |
| ALNY Alnylam Pharmaceuticals, Inc. | -102.0K | -85.7% | $30.71M | 0.101% |
| AXSM Axsome Therapeutics, Inc. | -96.3K | -45.0% | $23.58M | 0.566% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| UNH Unitedhealth Group Inc | +161.1K | $66.96M | 1.32% |
| HUM Humana Inc | +164.1K | $65.18M | 1.28% |
| ODTX Odyssey Therapeutics, Inc. | +3.00M | $56.15M | 1.1% |
| ARQT Arcutis Biotherapeutics, Inc. | +2.04M | $53.54M | 1.05% |
| WST West Pharmaceutical Services Inc | +70.6K | $25.35M | 0.498% |
| AURA Aura Biosciences, Inc. | +3.33M | $23.67M | 0.465% |
| SYRE Spyre Therapeutics, Inc. | +186.1K | $16.53M | 0.325% |
| WAT Waters Corp | +40.3K | $15.11M | 0.297% |
| MNPR Monopar Therapeutics | +157.4K | $14.58M | 0.287% |
| TVTX Travere Therapeutics, Inc. | +253.0K | $14.37M | 0.283% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| PFE Pfizer Inc | -1.95M | $54.66M | 1.29% |
| DHR Danaher Corp | -265.8K | $50.40M | 1.19% |
| BTSG BrightSpring Health Services, Inc. | -497.8K | $21.21M | 0.5% |
| AMGN Amgen Inc | -39.9K | $14.04M | 0.331% |
| ALHC Alignment Healthcare, Inc. | -791.0K | $13.94M | 0.328% |
| REGN Regeneron Pharmaceuticals, Inc. | -14.7K | $11.36M | 0.268% |
| CARL Carlsmed, Inc. | -1.25M | $11.34M | 0.267% |
| GILD Gilead Sciences, Inc. | -59.6K | $8.31M | 0.196% |
| HRTX Heron Therapeutics, Inc. | -9.82M | $7.85M | 0.185% |
| AVTX Avalo Therapeutics, Inc. | -475.2K | $7.09M | 0.167% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | EWTX Edgewise Therapeutics, Inc. | Healthcare | 15.52M | $630.52M | 12.4% | 0 | 0.0% | Unchanged | 14.4% |
| 2 | ELVN Enliven Therapeutics, Inc. | Healthcare | 6.78M | $343.91M | 6.76% | -1.18M | -14.9% | Reduced | 9.25% |
| 3 | LLY ELI LILLY & Co | Healthcare | 257.9K | $309.33M | 6.08% | +21.1K | +8.9% | Added | 0.03% |
| 4 | MBX MBX Biosciences, Inc. | Healthcare | 3.43M | $189.27M | 3.72% | -209.2K | -5.7% | Reduced | 7.15% |
| 5 | SVA Sinovac Biotech Ltd | Healthcare | 2.72M | $184.47M | 3.63% | 0 | 0.0% | Unchanged | 3.78% |
| 6 | AZN Astrazeneca Plc | Healthcare | 915.7K | $171.08M | 3.36% | +245.5K | +36.6% | Added | 0.06% |
| 7 | GPCR Structure Therapeutics Inc. | Healthcare | 2.21M | $118.58M | 2.33% | +734.0K | +49.7% | Added | 1.01% |
| 8 | SION Sionna Therapeutics, Inc. | Healthcare | 2.56M | $112.43M | 2.21% | -974.8K | -27.6% | Reduced | 5.66% |
| 9 | CRVS Corvus Pharmaceuticals, Inc. | Healthcare | 7.17M | $107.05M | 2.1% | 0 | 0.0% | Unchanged | 7.76% |
| 10 | AVBP ArriVent BioPharma, Inc. | Healthcare | 3.03M | $105.17M | 2.07% | 0 | 0.0% | Unchanged | 6.27% |
| 11 | GH Guardant Health, Inc. | Healthcare | 583.7K | $87.57M | 1.72% | +148.5K | +34.1% | Added | 0.44% |
| 12 | ARGX Argenx Se | Healthcare | 92.9K | $86.17M | 1.69% | -44.0K | -32.2% | Reduced | 0.15% |
| 13 | MRK Merck & Co., Inc. | Healthcare | 663.4K | $85.25M | 1.68% | 0 | 0.0% | Unchanged | 0.03% |
| 14 | QURE uniQure N.V. | Healthcare | 1.81M | $83.25M | 1.64% | -328.7K | -15.4% | Reduced | 2.61% |
| 15 | PRAX Praxis Precision Medicines, Inc. | Healthcare | 230.1K | $77.04M | 1.51% | +57.6K | +33.4% | Added | 0.79% |
Tip. Select a row to see that position’s full history at Orbimed Advisors.
As of its Q2 2026 13F filing, Orbimed Advisors LLC’s five largest positions were Edgewise Therapeutics, Inc. (EWTX) at 12.4%, Enliven Therapeutics, Inc. (ELVN) at 6.8%, ELI LILLY & Co (LLY) at 6.1%, MBX Biosciences, Inc. (MBX) at 3.7%, Sinovac Biotech Ltd (SVA) at 3.6% of the reported portfolio.
Orbimed Advisors LLC reported a 13F portfolio worth $5.09B across 110 positions for Q2 2026. That is up 19.8% from the previous quarter.
Its largest purchases by value were Unitedhealth Group Inc ($66.96M), Humana Inc ($65.18M), Odyssey Therapeutics, Inc. ($56.15M). It opened 30 new positions.
Its largest sales by value were Enliven Therapeutics, Inc. ($60.03M), Pfizer Inc ($54.66M), Disc Medicine, Inc. ($51.93M). It exited 16 positions entirely.
From the Form 13F-HR reports Orbimed Advisors LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.